文献速递冠心病

血小板-纤维蛋白凝块强度与血小板反应性预测PCI术后心血管事件

Platelet-fibrin clot strength and platelet reactivity predicting cardiovascular events after percutaneous coronary interventions.
PubMed 文献 · Eur Heart J · 2024-01-01

该研究基于韩国PCI注册数据(n=2512),采用血栓弹力图测血小板-纤维蛋白凝块强度(PFCS)、VerifyNow测血小板反应性,按两者水平分四组随访至4年。结果显示高PFCS与高血小板反应性对MACE有 additive 效应,HPR-PFCSHigh组MACE风险显著高于NPR-PFCSNormal组(HRadj 1.89)和HPR-PFCSNormal组(HRadj 1.60),联合评估可能优化PCI术后风险分层。

要点

  • 高PFCS(MA≥68 mm)与高血小板反应性(PRU>208)对MACE风险有叠加效应。
  • HPR-PFCSHigh组MACE发生率19.3%,显著高于NPR-PFCSNormal组7.5%。
  • NPR-PFCSNormal表型的大出血风险高于HPR-PFCSNormal(HRadj 3.12)。

核心结论

  • 在PCI患者中,PFCS与血小板反应性联合评估可增强术后风险分层,助力个体化抗栓治疗。

主要发现

  • 四组NPR-PFCSNormal、NPR-PFCSHigh、HPR-PFCSNormal、HPR-PFCSHigh的MACE发生率分别为7.5%、12.6%、13.4%、19.3%。
  • HPR-PFCSHigh组较NPR-PFCSNormal组MACE风险显著升高(HRadj 1.89;95%CI 1.23-2.91;P=.004)。
  • HPR-PFCSHigh组较HPR-PFCSNormal组MACE风险显著升高(HRadj 1.60;95%CI 1.12-2.27;P=.009)。
  • 全因死亡结果与MACE相似;NPR-PFCSNormal表型较HPR-PFCSNormal表型大出血风险更高(HRadj 3.12;95%CI 1.30-7.69;P=.010)。

关键数值与推荐

  • 高PFCS定义为血栓弹力图最大振幅≥68 mm,高血小板反应性定义为P2Y12反应单位>208。

临床怎么用

  • PCI术后可联合检测PFCS与血小板反应性,识别高MACE风险患者以强化抗栓治疗,并警惕NPR-PFCSNormal表型的出血风险。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Platelet-fibrin clot strength (PFCS) is linked to major adverse cardiovascular event (MACE) risk. However, the association between PFCS and platelet reactivity and their prognostic implication remains uncertain in patients undergoing percutaneous coronary intervention (PCI). METHODS: In PCI-treated patients (n = 2512) from registry data from January 2010 to November 2018 in South Korea, PFCS using thromboelastography and platelet reactivity using VerifyNow were measured. High PFCS (PFCSHigh) was defined as thromboelastography maximal amplitude ≥ 68 mm, and high platelet reactivity (HPR) was defined as >208 P2Y12 reaction units. Patients were stratified into four groups according to maximal amplitude and P2Y12 reaction unit levels: (i) normal platelet reactivity (NPR)-PFCSNormal (31.8%), (ii) HPR-PFCSNormal (29.0%), (iii) NPR-PFCSHigh (18.1%), and (iv) HPR-PFCSHigh (21.1%). Major adverse cardiovascular event (all-cause death, myocardial infarction, or stroke) and major bleeding were followed up to 4 years. RESULTS: High platelet reactivity and PFCSHigh showed an additive effect for clinical outcomes (log-rank test, P < .001). Individuals with NPR-PFCSNormal, NPR-PFCSHigh, HPR-PFCSNormal, and HPR-PFCSHigh demonstrated MACE incidences of 7.5%, 12.6%, 13.4%, and 19.3%, respectively. The HPR-PFCSHigh group showed significantly higher risks of MACE compared with the NPR-PFCSNormal group [adjusted hazard ratio (HRadj) 1.89; 95% confidence interval (CI) 1.23-2.91; P = .004] and the HPR-PFCSNormal group (HRadj 1.60; 95% CI 1.12-2.27; P = .009). Similar results were observed for all-cause death. Compared with HPR-PFCSNormal phenotype, NPR-PFCSNormal phenotype was associated with a higher risk of major bleeding (HRadj 3.12; 95% CI 1.30-7.69; P = .010). CONCLUSIONS: In PCI patients, PFCS and platelet reactivity demonstrated important relationships in predicting clinical prognosis. Their combined assessment may enhance post-PCI risk stratification for personalized antithrombotic therapy.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Kwon O, Ahn JH, Koh JS, et al. Platelet-fibrin clot strength and platelet reactivity predicting cardiovascular events after percutaneous coronary interventions. Eur Heart J. 2024. PMID: 38804262. doi:10.1093/eurheartj/ehae296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。